Indeed, previous evidence analyzing GBM tissues from study patients suggests that the duration of tumor control and survival advantage conferred by TMZ chemotherapy are highly associated with the MGMT activity: active expression of MGMT predicts early tumor progression and short survival time [9], [10], [11]. The gene discussed is MGMT; the disease is glioblastoma.